Back to Search
Start Over
Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies.
- Source :
-
American journal of obstetrics and gynecology [Am J Obstet Gynecol] 1990 Jan; Vol. 162 (1), pp. 148-54. - Publication Year :
- 1990
-
Abstract
- To examine the relationship between exogenous estrogen administration and endometrial cancer, we used data from the Cancer and Steroid Hormone Study, a multicenter, population-based case-control study. Estrogen replacement therapy for greater than or equal to 2 years was associated with an increased risk of both localized and extrauterine cancer (relative risk = 2.8, 95% confidence limits 1.6, 4.6; relative risk = 2.9, 95% confidence limits 0.9, 9.4, respectively). However, the latter finding was based on a small number of cases in which estrogen was used. Women who underwent estrogen replacement therapy for greater than or equal to 2 years had significantly elevated risks of endometrial cancer (2.1 for 2 to 5 years and 3.5 for greater than or equal to 6 years). An elevated risk persisted for greater than or equal to 6 years after discontinuation of therapy. Women who exclusively used conjugated equine estrogen preparations less than or equal to 0.625 mg had no increased risk of endometrial cancer. A history of oral contraceptive use appeared to reduce the risk of endometrial cancer associated with estrogen replacement therapy. However, these latter two potentially important findings were based on a small number of cases in which hormones were used.
Details
- Language :
- English
- ISSN :
- 0002-9378
- Volume :
- 162
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- American journal of obstetrics and gynecology
- Publication Type :
- Academic Journal
- Accession number :
- 2301483
- Full Text :
- https://doi.org/10.1016/0002-9378(90)90838-x